Leukemia

Progression of CAR-T trials in China

Progression of CAR-T trials in China

Jianxiang Wang • 2 Feb 2021

CAR-T trials to watch in China

CAR-T trials to watch in China

Jianxiang Wang • 2 Feb 2021

Infectious complications after CAR T-cell therapy

Infectious complications after CAR T-cell therapy

Joshua Hill • 10 Feb 2021

Infection prevention in patients receiving CAR T-cells

Infection prevention in patients receiving CAR T-cells

Joshua Hill • 10 Feb 2021

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Jordan Gauthier • 28 Jan 2021

CAR-T in myeloma: key players in the therapeutic landscape

CAR-T in myeloma: key players in the therapeutic landscape

Mohamad Mohty • 26 Jan 2021

Update on ARI-0001 for patients with CD19+ R/R malignancies

Update on ARI-0001 for patients with CD19+ R/R malignancies

Manel Juan Otero • 25 Jan 2021

ARI-0001 CART19 cells in R/R B-ALL with isolated extramedullary disease

ARI-0001 CART19 cells in R/R B-ALL with isolated extramedullary disease

Valentín Ortiz-Maldonado • 3 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021

An overview of the CAR T-cell therapy story

An overview of the CAR T-cell therapy story

Mohamad Mohty • 26 Jan 2021

The challenges of CAR T-cell therapy for pediatric B-ALL

The challenges of CAR T-cell therapy for pediatric B-ALL

Sara Ghorashian • 4 Feb 2021

ARI-0001 in CD19+ malignancies: next steps

ARI-0001 in CD19+ malignancies: next steps

Valentín Ortiz-Maldonado • 3 Feb 2021

CART19-BE-01: ARI-0001 in CD19+ malignancies

CART19-BE-01: ARI-0001 in CD19+ malignancies

Valentín Ortiz-Maldonado • 11 Oct 2020

Immunotherapy for T-cell malignancies

Immunotherapy for T-cell malignancies

Next questions in CAR-based therapies

Next questions in CAR-based therapies

Anti-CD19 CAR T-cells for adults

Anti-CD19 CAR T-cells for adults

David L. Porter • 9 Sep 2020